GRAIL filings document the public-company disclosures of a healthcare issuer developing and commercializing Galleri, a multi-cancer early detection test built on a targeted methylation-based platform. Its 8-K reports furnish operating and financial results, corporate presentations, clinical and regulatory updates, and other material events related to the company’s cancer detection business.
Regulatory filings also cover proxy governance, shareholder voting matters, board and leadership succession disclosures, emerging growth company status, and capital-structure activity. Recent records include securities purchase agreements, common stock and pre-funded warrant disclosures, resale registration-related materials, an at-the-market equity distribution agreement, and lease obligations, alongside exhibits and risk-oriented disclosures tied to GRAIL’s operations and financing needs.
GRAIL, Inc. reported solid growth for the quarter ended June 30, 2026, with total revenue up 26% year-over-year to $44.7 million. Galleri screening revenue rose 24% to $42.6 million as Galleri test volume increased 35% to more than 61,000 tests. For the first half of 2026, Galleri revenue grew 30% to $82.5 million on test volume growth of 42% to more than 117,000.
The company recorded a net loss of $110.2 million, an improvement of 3% versus the prior-year quarter, and a gross loss of $12.6 million. Non-GAAP metrics showed adjusted gross profit of $21.6 million and adjusted EBITDA of $(90.3) million. Cash, cash equivalents, and short-term marketable securities totaled $861.6 million as of June 30, 2026.
GRAIL highlighted positive clinical data from the large NHS-Galleri and PATHFINDER 2 multi-cancer early detection studies and completed a $110 million equity financing with Samsung, with plans to commercialize Galleri in South Korea and potentially other Asian markets. The company anticipates an FDA advisory committee in the fall to review its Premarket Approval application for the Galleri test.
BlackRock, Inc. filed an amended Schedule 13G reporting passive ownership of common stock of GRAIL, Inc. BlackRock reported beneficial ownership of 3,376,085 shares of GRAIL common stock, representing 7.9% of the outstanding class.
BlackRock reported sole voting power over 3,312,474 shares and sole dispositive power over 3,376,085 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no single client exceeds five percent of GRAIL’s outstanding common shares.
CHASE WILLIAM J reported acquisition or exercise transactions in this Form 4 filing.
GRAIL, Inc. director William J. Chase received a grant of 276 deferred stock units on July 15, 2026 under the deferred stock program and 2024 Equity Incentive Plan, in lieu of $20,568.49 of cash director fees, priced at $74.36 per share and vesting immediately, bringing his direct holdings to 42,978 shares.
SUMME GREGORY L reported acquisition or exercise transactions in this Form 4 filing.
GRAIL, Inc. director Gregory L. Summe received a grant of 427 deferred stock units under the company’s deferred stock program and 2024 Equity Incentive Plan in lieu of $31,787.67 of cash director fees, valued at $74.36 per unit and vesting immediately, bringing his directly reported holdings to 45,672 shares.
MIZELL STEVEN reported acquisition or exercise transactions in this Form 4 filing.
Steven Mizell, a director of GRAIL, Inc., received a grant of 268 deferred stock units as part of his director compensation. The award is valued at $74.36 per unit, or $19,945.21 in lieu of cash fees, and vests immediately. After this grant, he directly holds 42,830 shares of common stock.
CHASE WILLIAM J reported acquisition or exercise transactions in this Form 4 filing.
GRAIL, Inc. director William J. Chase received an equity award of 5,491 deferred stock units (DSUs) under the company’s 2024 Equity Incentive Plan. Each DSU represents the right to receive one share of common stock upon settlement.
The DSUs vest in full on the earlier of June 18, 2027 or the date of the next annual meeting of stockholders, subject to Chase’s continued service through the vesting date. Following this award, Chase directly holds 42,702 shares of GRAIL common stock.
GRAIL, Inc. director Steven Mizell received an equity award of 5,491 deferred stock units (DSUs) under the company’s 2024 Equity Incentive Plan, in lieu of 5,491 restricted stock units. The DSUs vest in full on June 18, 2027 or on the date of the next annual stockholder meeting, subject to continued service, and will settle into an equal number of common shares. After this grant, Mizell directly holds 42,562 shares. This is a compensation-related, non‑market acquisition rather than an open‑market share purchase.
SUMME GREGORY L reported acquisition or exercise transactions in this Form 4 filing.
GRAIL, Inc. director Gregory L. Summe received an equity award of 5,491 deferred stock units under the company’s 2024 Equity Incentive Plan. Each unit represents one share of common stock to be delivered at settlement.
The DSUs vest in full on the earlier of June 18, 2027 or the next annual stockholder meeting, subject to his continued service. After this grant, Summe directly holds 45,245 shares of GRAIL common stock.
Krevans Sarah reported acquisition or exercise transactions in this Form 4 filing.
GRAIL, Inc. reported that director Sarah Krevans received an equity award of 5,491 deferred stock units (DSUs) under the company’s 2024 Equity Incentive Plan. The DSUs vest in full on the earlier of June 18, 2027 or the next annual stockholder meeting, subject to continued service. Each DSU will settle into one share of common stock, and following this grant she holds 42,628 common shares directly.
GRAIL, Inc. held its Annual Meeting of Stockholders on June 18, 2026, with a quorum of 35,076,394 shares present out of 42,916,593 shares entitled to vote as of the April 22, 2026 record date.
Stockholders elected Class II directors Sarah Krevans and Steven Mizell to serve until the 2029 annual meeting. Krevans received 18,929,398 votes for and 2,972,804 withheld, while Mizell received 16,998,081 votes for and 4,904,121 withheld, in each case with 13,174,192 broker non-votes. Stockholders also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 34,611,318 votes for, 57,682 against, and 407,394 abstentions.